Rybelsus Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" Actually Means for an Approved Drug Like Rybelsus

Compassionate use and expanded access are terms that describe the same FDA regulatory pathway: access to an investigational or unapproved product outside of a clinical trial. The FDA's expanded access regulations are codified at 21 CFR Part 312, Subpart I, and the agency publishes guidance on individual patient access at fda.gov. Because Rybelsus already holds FDA approval for type 2 diabetes, a formal expanded access application is not required when a licensed physician prescribes it for that indication.

When Expanded Access Could Still Apply

A small subset of patients might consider expanded access for Rybelsus in two scenarios. First, a patient with a serious condition being enrolled in an ongoing Novo Nordisk trial who cannot meet eligibility criteria may request individual patient expanded access. Second, a patient seeking oral semaglutide for an unapproved indication (such as obesity without a diabetes diagnosis) could theoretically pursue this route. The FDA's bar for expanded access approval is that the potential benefit must outweigh the risk, and no comparable alternative exists.

The Practical Reality

For Rybelsus specifically, the practical answer is that almost no patient pursues formal FDA compassionate use. Physicians prescribe it off-label for obesity and prediabetes at their clinical discretion. The relevant question for most patients is not regulatory eligibility but cost. List price at major retail pharmacies runs approximately $935 per month in 2026, which places the drug out of reach without insurance or assistance.

A 2022 JAMA Internal Medicine analysis found that out-of-pocket costs for GLP-1 receptor agonists were a leading driver of non-adherence in patients with type 2 diabetes, with 30-day discontinuation rates 23% higher among patients paying full list price compared with those using manufacturer coupons. [1]

FDA Expanded Access: The Formal Pathway Explained

The FDA distinguishes three types of expanded access: individual patient access (including emergency use), intermediate-size population access, and widespread treatment protocols. For Rybelsus, only the individual patient pathway is plausible.

How to Submit an Individual Patient Request

The requesting physician completes FDA Form 3926 and submits it along with an Investigational New Drug (IND) application or a request for a waiver. For most approved drugs used off-label, the FDA will direct the physician to the manufacturer instead. Novo Nordisk's medical affairs team at 1-800-727-6500 is the starting point for any compassionate use inquiry involving semaglutide products.

Manufacturer Authorization

Even when the FDA grants expanded access, the manufacturer controls drug supply. Novo Nordisk has no publicly listed expanded access protocol for Rybelsus as of January 2026. The company's Named Patient Program operates in markets outside the United States where Rybelsus has not yet received local regulatory approval, but that program does not apply to US patients. Any US physician pursuing this route should expect a case-by-case review from Novo Nordisk medical affairs.

Timeline and Documentation

An emergency expanded access request can receive FDA authorization within 24 hours by phone, with written authorization to follow. Non-emergency individual patient requests typically take 30 days. The treating physician must submit an IRB notification or approval, informed consent documentation, and a treatment protocol. These requirements make formal expanded access impractical for routine cost-driven access needs.

The FDA's own statistics show that it approved more than 99% of expanded access requests submitted in fiscal year 2023, according to the agency's annual expanded access report. [2] Approval rate is not the bottleneck; cost and manufacturer supply are.

Novo Nordisk Patient Assistance Programs: The Primary Access Route

For uninsured and underinsured patients in the United States, Novo Nordisk's NovoCare program is the main legitimate access pathway. The program has two tiers that operate independently.

NovoCare Savings Card (Commercially Insured Patients)

Patients with commercial insurance (not Medicare or Medicaid) may use the NovoCare savings card to reduce their monthly copay. Eligible patients could pay as little as $10 per 30-day supply as of early 2026. The savings card covers up to $250 per fill, with an annual cap that Novo Nordisk adjusts periodically. Patients enroll at novocare.com or by calling 1-833-NOVO-411.

Key eligibility requirements include:

• Active US commercial prescription insurance that covers Rybelsus
• No federal or state government insurance (Medicare Part D, Medicaid, TRICARE)
• Age 18 or older

Novo Nordisk Patient Assistance Program (Uninsured or Underinsured)

Patients without insurance, or with insurance that excludes Rybelsus, may qualify for free medication through the Novo Nordisk Patient Assistance Program. Income eligibility is set at or below 400% of the federal poverty level (FPL). For a single adult, 400% FPL in 2026 is approximately $58,320 annually. For a family of four, the threshold is approximately $120,000.

Application steps:

1. Download and complete the application at novocare.com/pap.
2. Submit proof of income (recent tax return or pay stubs).
3. Have the prescribing physician sign the prescription attestation section.
4. Mail or fax the completed application to NovoCare.

Processing takes approximately three to four weeks. Once approved, medication ships directly to the prescribing physician's office or to a designated specialty pharmacy. Approvals are valid for 12 months and require annual re-certification.

A 2023 analysis published in Diabetes Care (N=14,200 real-world patients) found that manufacturer patient assistance programs reduced 90-day medication abandonment rates for GLP-1 receptor agonists by 41% compared with patients who received no cost support, though adherence still lagged behind patients with full insurance coverage. [3]

Medicare and Medicaid Patients: Different Rules Apply

Neither the NovoCare savings card nor the standard PAP covers patients with Medicare or Medicaid. These patients have separate options.

Medicare Part D Coverage

Rybelsus is covered on most Medicare Part D formularies, though tier placement varies. As of 2026, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D beneficiaries applies to all covered drugs including Rybelsus. Patients who previously faced catastrophic-phase costs above $6,000 annually now benefit from this statutory ceiling. [4]

Medicare Extra Help (Low Income Subsidy)

Medicare beneficiaries with limited income and resources may qualify for Extra Help, which reduces Part D premiums, deductibles, and copays to near zero. The Social Security Administration administers Extra Help enrollment at ssa.gov/extrahelp. The 2026 full subsidy income limit is approximately $21,000 for an individual.

Medicaid Coverage

Medicaid coverage for Rybelsus varies by state. Most state Medicaid programs cover semaglutide products for type 2 diabetes but may require prior authorization and step therapy (demonstrating failure of metformin and sulfonylurea first). Patients should contact their state Medicaid office or a benefits counselor to confirm formulary status.

Pharmacy Discount Programs and GoodRx-Style Tools

Patients who do not qualify for manufacturer programs and lack adequate insurance coverage have a third tier of options: third-party pharmacy discount cards.

How These Programs Work

Programs like GoodRx, RxSaver, and NeedyMeds negotiate group purchasing rates with pharmacy benefit managers and pass a portion of those savings to cardholders. For Rybelsus 14 mg (30 tablets), discount card prices at major chains ranged from approximately $780 to $870 in late 2025, representing roughly a 7 to 16% reduction from list price. [5]

These savings are meaningful but do not approach the $10 copay available through the NovoCare card. Patients should compare options before filling each prescription because prices vary by pharmacy location and change week to week.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs (costplusdrugs.com) had not listed branded semaglutide products as of January 2026, consistent with the absence of a generic. If oral semaglutide generics enter the market after patent expiration, this platform would likely become a low-cost source. Patent protection for the semaglutide molecule and its oral formulation (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate, SNAC, absorption enhancer) extends into the early 2030s according to Novo Nordisk's public patent filings. [6]

State Pharmaceutical Assistance Programs

Several states including Pennsylvania (PACE), New Jersey (PAAD), and Delaware (DPAP) run their own drug assistance programs for older adults and people with disabilities. Eligibility and covered drugs vary. Patients over 60 without adequate prescription coverage should check their state health department website for program details.

Off-Label Use and the Obesity Access Gap

Rybelsus is approved only for type 2 diabetes in the United States. Patients with obesity but no diabetes diagnosis cannot obtain an on-label prescription, and this creates a specific access problem.

What Physicians Can Prescribe Off-Label

Physicians may legally prescribe any FDA-approved drug off-label at their clinical judgment. Off-label prescribing of Rybelsus for obesity or prediabetes is not prohibited, but payers typically deny coverage for unapproved indications. The PIONEER 1 trial (N=703) showed that oral semaglutide 14 mg reduced HbA1c by 1.2 percentage points and body weight by 4.1 kg versus placebo at 26 weeks, [7] providing a published efficacy basis for off-label prescribing in early glycemic dysfunction. However, the weight loss with 14 mg oral semaglutide is substantially smaller than the 14.9% mean body weight reduction seen with subcutaneous semaglutide 2.4 mg (Wegovy) in the STEP-1 trial (N=1,961) at 68 weeks. [8]

Why Wegovy or Ozempic May Be More Appropriate for Obesity

Patients seeking semaglutide specifically for weight management without a diabetes diagnosis generally receive better outcomes from subcutaneous semaglutide 2.4 mg (Wegovy), which is FDA-approved for chronic weight management in adults with a BMI of 30 kg/m2 or greater, or BMI of 27 kg/m2 or greater with at least one weight-related comorbidity. Substituting Rybelsus for Wegovy to achieve weight loss is pharmacologically plausible but produces inferior results at approved doses and is unlikely to receive insurance coverage.

The American Diabetes Association's 2025 Standards of Care state: "For adults with type 2 diabetes and overweight or obesity who require greater glucose lowering than can be achieved with oral agents, GLP-1 receptor agonists with demonstrated cardiovascular benefit are preferred." [9] This guideline language does not endorse Rybelsus as a weight-loss drug independent of glucose control.

HSA and FSA Eligibility for Rybelsus

Rybelsus qualifies as an eligible expense under both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) when prescribed by a licensed physician for a qualifying medical condition (type 2 diabetes or an off-label use with a Letter of Medical Necessity).

Using HSA Dollars

Because Rybelsus requires a prescription, it automatically meets IRS Publication 502's definition of a qualified medical expense. Patients pay their pharmacy with an HSA debit card or submit receipts for reimbursement. There is no annual cap on prescription drug spending from an HSA.

FSA Rules and the Use-It-or-Lose-It Provision

FSA funds are subject to the use-it-or-lose-it rule (with an optional $640 carryover in 2026, per IRS Revenue Procedure 2025-19). Patients planning to use FSA dollars for Rybelsus should time their fills to avoid year-end forfeiture. A 90-day supply fill in November or December is a common planning strategy.

Letter of Medical Necessity for Off-Label Use

If a patient uses Rybelsus for an unapproved indication, the FSA/HSA plan administrator may request a Letter of Medical Necessity from the prescribing physician. The letter should state the diagnosis code, the clinical rationale for Rybelsus specifically, and the expected treatment duration. Most HSA custodians accept these letters without additional review.

Clinical Efficacy Context: Why Access Matters

Understanding what Rybelsus does clinically helps patients and advocates articulate the case for access.

PIONEER Program Results

The PIONEER clinical program enrolled more than 9,000 patients across 10 trials evaluating oral semaglutide against active comparators and placebo. PIONEER 3 (N=1,864) showed oral semaglutide 14 mg reduced HbA1c by 1.4 percentage points versus 0.9 percentage points for sitagliptin 100 mg at 26 weeks (P<0.001). [10]

PIONEER 6 Cardiovascular Safety

PIONEER 6 (N=3,183) was the cardiovascular outcomes trial required by the FDA as a condition of approval. The primary endpoint was major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke). Oral semaglutide demonstrated non-inferiority to placebo for MACE (hazard ratio 0.79, 95% CI 0.57 to 1.11). All-cause mortality was numerically lower in the semaglutide arm (hazard ratio 0.51, 95% CI 0.31 to 0.84), a finding the trial was not powered to confirm as a primary endpoint. [11]

Bioavailability Considerations

Oral semaglutide relies on SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) to support gastric absorption. Absolute bioavailability is approximately 1%, compared with 89% for subcutaneous semaglutide. The drug must be taken on an empty stomach with no more than 4 oz (120 mL) of plain water, followed by 30 minutes of fasting before any food, drink, or other oral medication. Failure to follow this regimen reduces absorption substantially and is a common reason for suboptimal clinical response. [12]

Compounded Semaglutide: Risks and Regulatory Status

Some patients have sought compounded oral or injectable semaglutide from 503A or 503B compounding pharmacies as a lower-cost alternative. The FDA's position, last updated in October 2025, is that semaglutide has been removed from the FDA drug shortage list, and that compounding pharmacies may no longer produce copies of FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) without meeting specific outsourcing conditions. [13] Compounded products lack FDA approval, may contain impurities, and are not substitutable for the approved drug.

Patients and physicians should avoid compounded oral semaglutide specifically. The SNAC absorption technology used in Rybelsus is proprietary and patent-protected. Compounded oral semaglutide formulations are unlikely to replicate the absorption profile, making dose comparisons unreliable.

A Practical Decision Guide for Patients Seeking Access

Patients facing cost barriers should work through the following sequence with their prescriber:

1. Confirm insurance coverage first. Call the member services number on the insurance card and ask specifically whether Rybelsus is on the formulary and what tier. Request a coverage exception or prior authorization if it is not covered.

2. Apply for the NovoCare savings card if commercially insured. Processing is immediate at novocare.com.

3. Apply for the Novo Nordisk PAP if uninsured and at or below 400% FPL. Allow three to four weeks for processing.

4. Check Medicare Extra Help or state pharmaceutical programs if on Medicare or Medicaid.

5. Use a pharmacy discount card as a bridge while awaiting PAP approval or while appealing an insurance denial.

6. Ask about 90-day supply fills. Many pharmacies offer a lower per-tablet price on 90-day supplies, and mail-order pharmacy copays are often lower than retail.

7. Use HSA/FSA funds to reduce the after-tax cost. At a 22% marginal tax rate, a $780 cash-pay prescription costs approximately $608 in pre-tax dollars through an HSA.

8. Discuss clinical alternatives with the prescriber. For patients with type 2 diabetes where cost is the primary barrier, dulaglutide (Trulicity) and liraglutide (Victoza) may have different formulary status. Metformin remains a low-cost first-line agent.

The NovoCare patient assistance program processed more than 600,000 applications for all Novo Nordisk products in 2023, according to the company's annual ESG report, suggesting the program has real operational capacity. [14]